PUBLISHER: The Business Research Company | PRODUCT CODE: 1751032
PUBLISHER: The Business Research Company | PRODUCT CODE: 1751032
Juvenile macular degeneration (Stargardt disease) treatment involves various approaches aimed at managing vision loss and enhancing the quality of life for individuals affected by this genetic eye condition. It is caused by genetic mutations that damage the macula, the central part of the retina, leading to gradual vision deterioration and difficulties with tasks such as reading and facial recognition.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary types of juvenile macular degeneration treatment are wet age-related macular degeneration and dry age-related macular degeneration. Wet age-related macular degeneration refers to a condition in which abnormal blood vessels form beneath the retina, causing fluid or blood leakage and rapid central vision loss. Treatments for juvenile macular degeneration include devices, medications, and surgery. These treatments focus on vision preservation, disease management, symptom relief, preventive care, and participation in clinical trials. They are provided through various channels such as hospitals, ambulatory surgical centers, and other healthcare settings.
The juvenile macular degeneration treatment market research report is one of a series of new reports from The Business Research Company that provides juvenile macular degeneration treatment market statistics, including the juvenile macular degeneration treatment industry global market size, regional shares, competitors with the juvenile macular degeneration treatment market share, detailed juvenile macular degeneration treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the juvenile macular degeneration treatment industry. These juvenile macular degeneration treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The juvenile macular degeneration treatment market size has grown strongly in recent years. It will grow from$1.28 billion in 2024 to $1.39 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth during the historic period can be attributed to several factors, including the rising prevalence of genetic eye disorders, increased investment in ophthalmic research, a growing focus on pediatric eye care, the increasing prevalence of vision impairment among children, and the expanding integration of artificial intelligence in eye care diagnostics.
The juvenile macular degeneration treatment market size is expected to see strong growth in the next few years. It will grow to$1.88 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth during the forecast period can be attributed to factors such as the growing geriatric population, an increase in ophthalmic biotechnology startups, a stronger focus on targeted drug delivery systems, a rise in the number of clinical trials, and greater investment in gene therapy. Key trends during this period include advancements in genetic testing, the development of gene therapies, progress in stem cell research, regulatory support for innovative treatments, and the adoption of personalized medicine approaches.
The growing prevalence of retinal disorders is expected to drive the expansion of the juvenile macular degeneration treatment market in the coming years. Retinal disorders, which affect the light-sensitive layer of the eye and lead to vision impairment or loss, are becoming more prevalent, particularly due to the rise in diabetes and conditions such as diabetic retinopathy, which gradually damages the retina. Juvenile macular degeneration treatments are essential in managing these retinal conditions by preserving vision through early intervention, particularly for young patients. For example, a November 2024 report from Retina Australia estimates that approximately 19,000 individuals in Australia, or 1 in 1,380 people, live with inherited retinal diseases (IRDs). Additionally, the National Eye Institute predicts that the number of Americans with advanced age-related macular degeneration (AMD) will grow from 2.1 million to 3.7 million by 2030. These statistics underline the increasing need for juvenile macular degeneration treatments, driving market growth.
Companies in the juvenile macular degeneration treatment market are focusing on cutting-edge gene therapies, such as dual adeno-associated viral (AAV) vectors, to improve gene therapy delivery and treatment outcomes. Dual AAV vectors utilize two AAV vectors to deliver large therapeutic genes that exceed the capacity of a single AAV, making gene therapy more effective. For instance, in March 2025, SpliceBio, a Spain-based biotechnology company, announced the first patient dosing in its Phase 1/2 ASTRA study for SB-007. This dual AAV vector gene therapy aims to restore full-length ABCA4 protein expression and could offer a potential treatment for Stargardt disease, a form of juvenile macular degeneration that currently has no approved treatments. This breakthrough represents a significant advancement in treating rare retinal diseases.
In July 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, acquired IVERIC Bio Inc., a US-based company specializing in juvenile macular degeneration treatments, particularly for Stargardt disease. Through this acquisition, Astellas aims to enhance its ophthalmology portfolio, accelerate the development of innovative treatments for retinal diseases, and expand its expertise in gene therapy and complement inhibition. This acquisition strengthens Astellas' position in the juvenile macular degeneration treatment market, positioning it to offer novel solutions for conditions such as Stargardt disease and geographic atrophy.
Major players in the juvenile macular degeneration treatment market are F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, AbbVie Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Santen Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Samsung Bioepis Co. Ltd., Spark Therapeutics Inc., Polpharma Biologics S.A., OrCam Technologies Ltd., Alkeus Pharmaceuticals Inc., Bioeq AG, NuEyes Technologies Inc., Coherus BioSciences Inc., eSight Eyewear Inc., MeiraGTx Holdings plc, and Kubota Pharmaceutical Holdings Co. Ltd.
North America was the largest region in the juvenile macular degeneration treatment market in 2024. The regions covered in juvenile macular degeneration treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the juvenile macular degeneration treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The juvenile macular degeneration treatment market consists of revenues earned by entities by providing services such as vision therapy, low vision rehabilitation, genetic counseling, nutritional counseling, and psychological support for vision loss management. The market value includes the value of related goods sold by the service provider or included within the service offering. The juvenile macular degeneration (JMD) treatment market also includes sales of prescription eyewear, low vision aids, braille displays, specialty lighting devices, and dietary supplements for eye health. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Juvenile Macular Degeneration Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on juvenile macular degeneration treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for juvenile macular degeneration treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The juvenile macular degeneration treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.